Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimasartan/Amlodipine/Rosuvastatin in Hypertension and Dyslipidemia
NCT03156842Phase 3Completed
- Sponsor
- Boryung
- Start
- May 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension and dyslipidemia comparing Fimasartan/Amlodipine/Rosuvastatin, Fimasartan/Amlodipine and Fimasartan/Rosuvastatin (3 arms). Primary endpoints: Low-Density Lipoprotein Cholesterol at 8 weeks and Sitting Systolic Blood Pressure at 8 weeks. Started May 2017; status: completed.
02
Drugs
fimasartanamlodipinerosuvastatin
03
Conditions
essential hypertensiondyslipidemia
Beyond the preview
Go deeper on NCT03156842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156842.